Etomidate in Dogs & Cats
Generic: Etomidate
Etomidate is a short-acting, non-barbiturate intravenous anesthetic agent used primarily for the induction of general anesthesia in patients with significant cardiovascular compromise.
This medication is intended for dogs and cats.
Overview
Etomidate is a unique carboxylated imidazole derivative that provides rapid, short-duration induction of anesthesia with minimal effects on the cardiovascular system. Unlike older agents like Thiopental or Methohexital, etomidate maintains cardiac output and blood pressure, making it the preferred choice for critically ill animals or those presenting with pre-existing heart disease. It produces a stable hemodynamic profile, though it is often used in combination with sedatives such as Diazepam (Anesthetic) or Butorphanol (Anesthetic) to reduce myoclonus (muscle twitching) during the induction phase. Because it offers little to no analgesia, it must be supplemented with appropriate pain management protocols if surgery is to be performed.
The clinical utility of etomidate is largely defined by its high safety margin in compromised patients, such as those with severe shock or cardiomyopathy. While Propofol is frequently utilized for routine inductions due to its ease of use and recovery characteristics, etomidate remains the gold standard when blood pressure stability is the primary clinical objective. Veterinary professionals often choose to pair etomidate with Dexmedetomidine (Anesthetic) or Xylazine to improve muscle relaxation and provide a smoother transition to inhalant anesthetics like Isoflurane or Sevoflurane.
It is important to note that etomidate induces temporary adrenocortical suppression by inhibiting the enzyme 11-beta-hydroxylase. While this effect is typically transient and rarely clinically significant in healthy patients during a single-use application, clinicians weigh this factor in patients with endocrine disorders. Unlike Acepromazine (Anesthetic), which can cause significant vasodilation, etomidate preserves autonomic reflexes and maintains systemic vascular resistance. This makes it an invaluable tool in the emergency setting where the patient's cardiovascular system is already taxed by the underlying disease process.
What It Treats
- Induction of anesthesia: Used as a fast-acting agent to place an endotracheal tube in critically ill patients.
- Hemodynamic stabilization: Chosen specifically for patients where blood pressure maintenance is critical during the induction of anesthesia.
- Patients with cardiac disease: The drug of choice for animals with significant mitral valve disease or dilated cardiomyopathy.
How It Works
Etomidate functions by enhancing the effects of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the brain. By binding to specific GABA-A receptor subunits, it increases the influx of chloride ions into neurons, which leads to hyperpolarization and a decrease in neuronal excitability. This rapid central nervous system depression results in loss of consciousness within seconds. Unlike many other intravenous anesthetics, etomidate exerts very little influence on the sympathetic nervous system or the baroreceptor reflexes. This lack of cardiac depression is the primary reason it is favored in animals with diminished cardiac reserve. It effectively shuts down cortical activity while sparing the medullary centers that regulate heart rate and blood pressure.
Dosage
Dosage is strictly calculated based on the patient's body weight, current health status, and pre-medication protocol. Because etomidate is a potent anesthetic, only a licensed veterinarian can determine the appropriate dose. Do not attempt to calculate or adjust doses without veterinary guidance, as individual patient requirements vary drastically based on physical condition.
Administration
Etomidate is administered strictly via the intravenous route by a trained veterinary professional. It is typically given as a bolus injection over 30 to 60 seconds to minimize the incidence of myoclonus. The injection must be performed carefully to avoid perivascular extravasation, which may cause local tissue irritation, and in cases of hemolysis-prone patients, the administration rate is carefully monitored to prevent adverse blood-related reactions.
Storage
Etomidate should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It must be protected from light and kept in a secure area to prevent unauthorized access. Once a vial is opened, it should be used promptly according to the manufacturer's recommendations, as it does not contain long-acting preservatives.
Contraindications
Etomidate is contraindicated in patients with known hypersensitivity to the drug or imidazole derivatives. While its primary benefit is cardiovascular stability, it should be used with extreme caution in patients with pre-existing adrenal insufficiency (such as Addison's disease), as the medication further suppresses adrenal function, which could trigger an addisonian crisis. Furthermore, because the drug is formulated in propylene glycol in some veterinary products, it is not recommended for continuous rate infusion (CRI) due to the risk of hemolysis and renal injury. Clinical judgment should be exercised when a patient has severe hepatic or renal dysfunction, as metabolism of the drug may be prolonged, extending the recovery period.
Interactions
Etomidate may potentiate the effects of other CNS depressants, including opioids and benzodiazepines. When used concurrently with these agents, a lower dose of etomidate is often required to achieve the desired plane of anesthesia, preventing excessive respiratory or central nervous system depression. There are no major problematic metabolic interactions with standard inhalant anesthetics; in fact, the transition to agents like [Desflurane](/medications/desflurane-in-dogs-and-cats) or [Isoflurane](/medications/isoflurane-in-dogs-and-cats) is a standard part of the protocol. However, clinicians should avoid mixing etomidate in the same syringe with other medications, as the low pH of the drug may cause precipitation or physical incompatibility.
Side Effects
- Myoclonus (involuntary muscle twitching or jerking)
- Adrenocortical suppression (transient decrease in cortisol production)
- Pain upon injection at the site of administration
- Post-induction hemolysis (observed in rare cases with repeated doses)
- Gagging, retching, or transient apnea
- Decreased temperature regulation during recovery
Sources & References
Frequently Asked Questions
This information is educational only and not a substitute for professional veterinary advice. Always consult a licensed veterinarian before starting or changing any medication.
